Introduction
A century ago Paul Ehrlich first used the term eosinophil to describe this polymorphonuclear leucocyte. Its existence had first been hinted at by Wharton Jones in 1846. The association of eosinophilia with metazoan parasitic infection has become well established since it was first recorded in ancylostomiasis in 1891 by Muller and Rieder. Eosinophilia occurring with allergies and atopic conditions has been noted since the earliest identification of this cell. Recently interest has become increasingly focused on a number of disorders in which eosinophilia occurs for no apparently identifiable cause and which have been grouped together as the hypereosinophilic syndrome (Hardy and Anderson, 1968) .
Two patients with this syndrome are described whose outcomes have been totally different.
Case reports Case I
A 26-year-old policeman was first seen in 1976 with an 18-month history of sudden attacks of marked swelling of eyes (Beeson and Bass, 1977) .
In 1975 Chusid and his colleagues established criteria in an attempt to define this syndrome. These criteria include a persistent eosinophilia of 1-5 x 109/ for longer than 6 months, or death before 6 months associated with signs and symptoms of hypereosinophilic disease, lack of evidence of known causes of eosinophilia, and multiple organ involvement. Both the present patients satisfied these criteria. The heart and bone marrow are most frequently involved but the CNS, skin and muscle, the gastrointestinal tract including liver, lungs, kidneys and the lymphatic system have all been commonly reported to be affected. Initial observations indicated a uniformly grave prognosis (Benvenisti and Ultmann, 1969; Roberts, Liegler and Carbone, 1969; Chusid et al., 1975) . Recent reports however suggest a more variable course, with a more favourable outcome in certain cases (Resnick and Myerson, 1971; Parillo, Fauci and Wolff, 1978; Bush et al., 1978) . Grave prognostic signs are said to include a total white cell count greater than 100 x 109/, eosinophil myeloblasts in the peripheral blood, the presence of leukaemic markers and the appearance of congestive heart failure (Parillo et al., 1978) . Cardiac disease has been implicated as the major cause of death in this syndrome.
The first patient seems to fit in the small group of patients who have been reported as having a relatively benign form of the disease compatible with a mild prolonged course. As he had no evidence of significant progressive organ involvement he received no treatment, but is being carefully and regularly followed-up. Parillo (Parillo et al., 1978) . Busulphan, chlorambucil, 6-mercaptopurine and methotrexate have all been tried and found to have no significant effect. It has been claimed that hydroxyurea has achieved good results in treating patients unresponsive to corticosteroid (Parillo et al., 1978) . The present authors had no opportunity to try using hydroxyurea in their second case. Dramatic improvement has also been reported in a single case by using a continuous-flow cell separator to remove circulating eosinophils (Ellmann, Miller and Rappeport, 1974 ).
It appears that the hypereosinophilic syndrome embraces a spectrum of disease entities. It is perhaps best regarded as a clinical and pathological continuum of conditions reflecting a hypersensitivity or autoimmune process and which seem to range from the benign to the rapidly fatal forms, having as their common denominator infiltrative eosinophilia (Parillo et al., 1979 
